TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12151930
Drug: Ox1 l
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ox1 l (oxygen, LFA)
Study: 12151930
Drug: NOx1 l
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOx1 l (oxygen-nitrous oxide, LFA after 10 min high fresh gas flow)
Study: 10417507
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion into the brachial artery at a rate of 2 ml/100 ml forearm min‐1
Study: 2855478
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no saline infusion)
Study: 7305608
Drug: Clonidine hydrochloride,
Normalized name: CloNIDine Hydrochloride, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine hydrochloride, peak mean dose of 16 micro g/kg/day, administered for 10 to 11 days
Study: 30227423
Drug: H2‐O2 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2‐O2 (6 L per min, H2:O2 = 2: 1) for 15 min
Study: 30227423
Drug: O2 (3
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: O2 (3 L per min) for 15 min
Study: 24611442
Drug: Desvenlafaxine 10-100
Normalized name: desvenlafaxine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine 10-100 mg/day (children) or 25-200 mg/day (adolescents) for 8 months
Study: 22700995
Drug: Ganitumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganitumab (12 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Study: 22700995
Drug: Conatumumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conatumumab (10 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Study: 22700995
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with gemcitabine (1000 mg/m2 on days 1, 8, and 15 of each 28-day cycle)
Study: 13129985
Drug: Azithromycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (600 mg/d for 3 days during week 1, then 600 mg/wk during weeks 2‐12; n = 3879)
Study: 10373219
Drug: Control (heparin)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (heparin)
Study: 12024138
Drug: Endoscopic epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endoscopic epinephrine injection
Study: 1983848
Drug: Heat probe
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heat probe treatment
Study: 6836750
Drug: Adjuvant hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant hormone therapy (gestonorone caproate, 200 mg/week for 1 year)
Study: 30470892
Drug: Myofascial release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial release treatment (MR)
Study: 30470892
Drug: Placebo manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo manual lymphatic drainage treatment (PMLD)
Study: 29744966
Drug: Self-Book© art
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Book© art therapy
Study: 22695903
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 500 mg twice daily
Study: 20577914
Drug: Lateral-to-medial laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral-to-medial laparoscopic right hemi-colectomy (Group L)
Study: 17379431
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy (IFRT)
Study: 17379431
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HD-CT) followed by IFRT
Study: 15679751
Drug: Weekly telephone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly telephone monitoring and counseling combined with a support group in the first 4 weeks (TEL)
Study: 15679751
Drug: Twice-weekly standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly standard group counseling (STND)
Study: 15679751
Drug: Twice-weekly individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly individualized relapse prevention (RP)
Study: 12162978
Drug: Rhys‐Davies exsanguinator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhys‐Davies exsanguinator supplemented by a 500 ml bag of intravenous fluid
Study: 2361795
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (120 mg/day)
Study: 2361795
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (60 mg/day)
Study: 23547487
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral-B Indicator 30 Compact Soft Toothbrush)
Study: 21454149
Drug: 10% C‐β‐D‐xylopyranoside‐2‐hydroxy‐propane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% C‐β‐D‐xylopyranoside‐2‐hydroxy‐propane (C‐xyloside) cream
Study: 17016596
Drug: CKLQ (Cobrotoxin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKLQ (Cobrotoxin, tramadol hydrochloride, ibuprofen)
Study: 1418362
Drug: Velnacrine 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine 300 mg/day
Study: 1418362
Drug: Velnacrine 225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velnacrine 225 mg/day
Study: 31481453
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) for stage IIIC
Study: 30368249
Drug: 0.1% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% CHX solution (control group)
Study: 26920601
Drug: Evolocumab (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (140 mg subcutaneously every 2 weeks or 420 mg subcutaneously every month)
Study: 26920601
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo injections
Study: 23207160
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockers (ARB) - candesartan
Study: 23207160
Drug: Beta-blockers -
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers - metoprolol
Study: 23207160
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ARB and beta-blockers
Study: 17062657
Drug: Once-weekly strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly strength training (1 day/week)
Study: 17062657
Drug: Twice-weekly strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly strength training (2 days/week)
Study: 15799683
Drug: Efalizumab 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalizumab 1.0 mg/kg, administered subcutaneously once weekly for 12 weeks
Study: 10211014
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural administration of ropivacaine
Study: 10211014
Drug: Epidural ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ropivacaine and patient‐controlled analgesia (PCA) with i.v. morphine
Study: 25803245
Drug: Intra‐articular 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐articular 20 ml of 0.25% bupivacaine 20 minutes before the start of the operation (preemptive: PE)
Study: 25803245
Drug: No intra‐articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intra‐articular injection (control group: CG)
Study: 23769553
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate and progesterone capsule (group B, n = 32)
Study: 21920203
Drug: Tibial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibial and common fibular nerve block using percutaneous nerve stimulator with 10 mL of levobupivacaine injected at each nerve site.
Study: 18218084
Drug: 5-option decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-option decision aid (FOBT, sigmoidoscopy, combination of FOBT and sigmoidoscopy, colonoscopy, barium enema)
Study: 10981219
Drug: Di-Te-Ki-Pol vaccine
Normalized name: di-isopropylammonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Di-Te-Ki-Pol vaccine 'SSI'
Study: 10981219
Drug: DT-IPV plus
Normalized name: DT, IPV adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: DT-IPV plus wholecell pertussis vaccine
Study: 29222892
Drug: Oral Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Nutritional Supplements (Peptamen)
Study: 22811009
Drug: Bortezomib plus
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib plus Bevacizumab (1.3 mg/m² on days 1, 4, 8, and 11 of each 21-day cycle; Bevacizumab 15 mg/kg on day 1 of each cycle)
Study: 22811009
Drug: Bortezomib monotherapy
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib monotherapy (1.3 mg/m² on days 1, 4, 8, and 11 of each 21-day cycle)
Study: 16539916
Drug: Salbutamol and
Normalized name: salbutamol and budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol and terbutaline doses delivered via MDI with spacer (half the child's weight)
Study: 16539916
Drug: Salbutamol and
Normalized name: salbutamol and budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol and terbutaline doses delivered via MDI with spacer (one-third of the child's weight)
Study: 12562445
Drug: Esomeprazole, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole, 20 mg once daily
Study: 11908405
Drug: 5.3% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.3% hydrogen peroxide tooth-bleaching gel, used twice daily for 2 weeks
Study: 11908405
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between peroxide gel and placebo
Study: 8296377
Drug: Artemether (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether (5 days intramuscular regimen)
Study: 3520308
Drug: Flunarizine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (up to 0.25 mg/kg/day)
Study: 23430885
Drug: Counting gram
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counting gram protein exchanges (1g=50‐mg Phenylalanine)
Study: 23430885
Drug: Counting Phe
Normalized name: Phe
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Counting Phe unit exchanges (1unit=15‐mg Phenylalanine)
Study: 20098447
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of gestational diabetes mellitus
Study: 14999111
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin (conjugated equine estrogens 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day)
Study: 8983284
Drug: Ondansetron 5
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 5 mg/m2
Study: 8983284
Drug: Ondansetron 10
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron 10 mg/m2
Study: 8983284
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment arms (5 mg/m2 and 10 mg/m2)
Study: 1751459
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of gentamicin at the end of the cataract procedure (Group G)
Study: 1751459
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of gentamicin and a cellulose wick drain (Group GW)
Study: 7064901
Drug: Reference dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference dose of inorganic iron (3 mg)
Study: 31087065
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation at discharge by a clinical pharmacist, a prescription check for formal flaws, interactions and missing therapy durations.
Study: 28340157
Drug: Cervical lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cervical lateral glide (CLG) treatment
Study: 28340157
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - waiting list for treatment
Study: 10920403
Drug: Sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 100 mg plus naproxen sodium 550 mg
Study: 10920403
Drug: Sumatriptan 100
Normalized name: sumatriptan 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 100 mg plus placebo
Study: 8959522
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy with lansoprazole (30 mg o.d.) for 8 weeks plus clarithromycin (200 mg b.i.d.) or amoxicillin (250 mg q.i.d.) for 2 weeks
Study: 8959522
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with lansoprazole (30 mg o.d.) and ecabet sodium (1.0 g b.i.d.) for 8 weeks plus clarithromycin (200 mg b.i.d.) or amoxicillin (250 mg q.i.d.) for 2 weeks
Study: 1413183
Drug: Venoruton (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton (300 mg x 3)
Study: 30208960
Drug: Junctional Emergency
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Junctional Emergency Treatment Tool (JETT)
Study: 26671007
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT), 24 IU
Study: 17572521
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl chloride spray (EC)
Study: 17572521
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic Ametop (TA)
Study: 15661445
Drug: Intravenous dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dextromethorphan (DM) 0.5 mg/kg
Study: 10567867
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of recombinant tissue plasminogen activator (rtPA) and intravenous heparinization (n = 23)
Study: 10567867
Drug: early-phase hemodilution
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: early-phase hemodilution therapy (n = 22)
Study: 10567867
Drug: late-phase hemodilution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: late-phase hemodilution therapy (n = 13)
Study: 8724107
Drug: Lp(a) ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) ≥ 20 mg/dl
Study: 8724107
Drug: Lp(a) <
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lp(a) < 20 mg/dl
Study: 2035283
Drug: 10.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.5 g fish oil daily
Study: 2035283
Drug: 5.25 g
Normalized name: LIDOCAINE 5.25 g in 100 g RECTAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25 g fish oil daily
Study: 6786855
Drug: Carbenoxolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (50 mg Biogastron duodenal three times daily)
Study: 22075648
Drug: Osmotic-release oral
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic-release oral system (OROS) methylphenidate
Study: 19433778
Drug: ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (5 mg/d) at bedtime
Study: 19433778
Drug: ramipril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril (5 mg/d) on awakening
Study: 11222463
Drug: Etanercept 5
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 5 mg/m2
Study: 11222463
Drug: Etanercept 12
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 12 mg/m2
Study: 7912097
Drug: Zidovudine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (1000 mg daily in two divided doses)
Study: 22099891
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen combined with 1000 mg acetaminophen
Study: 7019840
Drug: Pancuronium bromide
Normalized name: Pancuronium Bromide
DrugBank: Pancuronium (DB01337)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pancuronium bromide (administered for 12 hours)
Study: 7019840
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no pancuronium bromide, administered for 12 hours)
Study: 22905878
Drug: Perampanel (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (up to 12 mg/day)
Study: 10367725
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (300 mg x kg(‐1) body mass)
Study: 2200896
Drug: Thiamylal 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal 4 mg.kg‐1
Study: 29045769
Drug: Active drugs
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drugs (olanzapine, quetiapine, risperidone)
Study: 26464455
Drug: Suvorexant (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (40 mg) with alcohol (0.7 g/kg)
Study: 26464455
Drug: Suvorexant (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (40 mg) alone
Study: 26464455
Drug: Alcohol (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.7 g/kg) alone
Study: 23261493
Drug: N-acetylcysteine (1200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (1200mg NAC twice daily)
Study: 21876071
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg/d
Study: 21876071
Drug: Telmisartan 160
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 160 mg/d
Study: 18611293
Drug: Medication augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication augmentation
Study: 22449646
Drug: Medication switch
Normalized name: witch hazel Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication switch
Study: 6375889
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg qid)
Study: 6375889
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg qid)
Study: 6375889
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg qid) + Captopril (25 mg qid)
Study: 16713921
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (90 g total, infused over 3 consecutive days, repeated after 3 months)
Study: 2628131
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 250 mg orally twice daily for 10 days
Study: 2628131
Drug: Amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 250 mg orally three times daily for 10 days
Study: 786190
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (No steroid)
Study: 786190
Drug: Steroid-treated patients
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid-treated patients (DMP + MPS)
Study: 23497981
Drug: 1.5 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 μg/kg atomized dexmedetomidine
Study: 21570054
Drug: Systemic cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic cyclosporine (CsA) administered for at least 6 months with a blood CsA concentration of approximately 800 ng/mL.
Study: 21570054
Drug: Systemic cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic cyclosporine (CsA) administered for at least 6 months.
Study: 17042889
Drug: l-carnitine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine (15 mg/kg/day)
Study: 12601631
Drug: Beraprost sodium
Normalized name: beraprost sodium
DrugBank: Beraprost (DB05229)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beraprost sodium (3 years treatment)
Study: 10604887
Drug: h5G1.1‐scFv at
Approvals — FDA: no, EMA: no, PMDA: no
Description: h5G1.1‐scFv at 2 mg/kg
Study: 10604887
Drug: h5G1.1‐scFv at
Approvals — FDA: no, EMA: no, PMDA: no
Description: h5G1.1‐scFv at 1 or 2 mg/kg
Study: 8542173
Drug: Neoadjuvant and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant and primary medical treatment
Study: 6140091
Drug: prenalterol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: prenalterol (40 to 120 mg/day)
Study: 27253214
Drug: Group psychoeducation
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychoeducation (GP) - 10 weekly sessions followed by 8 booster sessions over 2 years
Study: 25354581
Drug: 1xH5N1‐AS (neutralising
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1xH5N1‐AS (neutralising antibodies)
Study: 25354581
Drug: 2xH5N1‐AS (neutralising
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2xH5N1‐AS (neutralising antibodies)
Study: 17555530
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral risedronate (35 mg) with vitamin D and calcium
Study: 12432190
Drug: Azithromycin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (5 days treatment)
Study: 12432190
Drug: Azithromycin (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (14 days treatment)
Study: 10080586
Drug: Doxorubicin-based neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-based neoadjuvant chemotherapy
Study: 7030645
Drug: Amcinonide cream
Normalized name: Amcinonide Cream
DrugBank: Amcinonide (DB00288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amcinonide cream 0.1 percent
Study: 7030645
Drug: Halcinonide cream
Normalized name: Halcinonide Cream
DrugBank: Halcinonide (DB06786)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Halcinonide cream 0.1 percent